A clinical study to assess the safety and immunogenicity of attenuated measles vaccine administered intranasally to healthy adults

Human Vaccines

Volumn 3, Issue 2, 2007, Pages 54-58

  Simon, Jakub K ^a,d   Pasetti, Marcela F ^a   Viret, Jean François ^b   Mischler, Robert ^b   Muñoz, Alma ^c   Lagos, Rosanna ^c   Levine, Myron M ^a   Campbell, James D ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b Berna Biotech AG   (Switzerland)

^c HOSPITAL ROBERTO DEL RÍO   (Chile)

^d Center for Vaccine Development   (United States)

Author keywords

Immunogenicity; Intranasal; Measles; Safety; Vaccine

Indexed keywords

MEASLES VACCINE; PLACEBO;

ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; BURNING SENSATION; CALCULATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSPNEA; EPISTAXIS; ERYTHEMA; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; MALAISE; MALE; NEEDLE; NORMAL HUMAN; OUTCOME ASSESSMENT; PAIN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; RASH; RHINORRHEA; SEROCONVERSION; SERODIAGNOSIS; SWELLING; TACHYPNEA; TREATMENT OUTCOME; VIRUS PLAQUE; VIRUS SHEDDING;

EID: 33947658884     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.2.3877     Document Type: Article

References (25)

1. Progress in reducing global measles deaths, 1999-2004. MMWR Morb Mortal Wkly Rep 2006; 55:247-9.
2. Redd SC. Measles Vaccine. In: Plotkin S, Orenstein W, eds. Vaccines 2006; 222-66.
3. Weekly epidemiological record; measles vaccines world health organization position paper. World Wide Web 2004; 130-142, ([cited 2006 Apr 26]. Available from: URL: http://www. who.int/immunization/documents/positionpapers/en/index. html).
4. World health organization and united nation's children's fund global immunization vision and strategy. World Wide Web 2005; 8, ([cited 2006 Apr 26]. Available from: URL: http:// www.who.int/vaccines/GIVS/).
5. Jodar L, Duclos P, Milstien JB, Griffiths E, Aguado MT, Clements CJ. Ensuring vaccine safety in immunization programmes-a WHO perspective. Vaccine 2001; 19(13-14):1594-605.
6. World health organization immunization, vaccines, and biologicals: Strategic plan 2006-2009. World Wide Web 2005; 8, ([cited 2006 Apr 26]. Available from: URL: http:// www.who.int/immunization/aboutus/en/).
7. Pasetti MF, Barry EM, Losonsky G, Singh M, Medina-Moreno SM, Polo JM, Ulmer J, Robinson H, Sztein MB, Levine MM. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J Virol 2003; 77:5209-17.
8. Fernandez-de CJ, Kumate-Rodriguez J, Sepulveda J, Ramirez-Isunza JM, Valdespino-Gomez JL. Measles vaccination by the aerosol method in Mexico. Salud Publica Mex 1997; 39:53-60.
9. Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization: A review. Biologicals 1997; 25:323-38.
10. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Pteblud SR, Orenstein WA. Measles antibody: Reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
11. Tapia MD, Sow SO, Medina-Moreno S, Lim Y, Pasetti MF, Kotloff K, Levine MM. A sero-survey to identify the window of vulnerability to wild-type measles among infants in rural Mali. Am J Trop Med Hyg 2005; 73:26-31.
12. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 1981; 3:251-60.
13. Black FL, Sheridan SR. Studies on an attenuated measles virus vaccine. IV. Administration of vaccine by several routes. N Engl J Med 1960; 263:165-9.
14. Okuno Y. Vaccination with egg passage measles virus by inhalation. Am J Dis Child 1962; 103:381-4.
15. Okuno Y, Ueda S, Hosai H, Kitawaki T, Nakamura K, Chiang TP, Okabe S, Onaka M, Toyoshima K. Studies on the combined use of killed and live measles vaccines. II. Advantages of the inhalation method. Biken J 1965; 8:81-5.
16. Ueda S, Hosai H, Minekawa Y, Okuno Y. Studies on the combined use of killed and live measles vaccines. III. Conditions for the "take" of live vaccine. Biken J 1966; 9:97-101.
17. Sabin AB. Immunization against measles by aerosol. Rev Infect Dis 1983; 5:514-23.
18. Kress S, Schluederberg AE, Hornick RB, Morse LJ, Cole JL, Slater EA, McCrumb FR Jr. Studies with live attenuated measles-virus vaccine. II. Clinical and immunologic response of children in an open community. Am J Dis Child 1961; 101:701-7.
19. Beck M, Smerdel S, Dedic I, Delimar N, Rajninger-Miholic M, Juzbasic M, Manhalter T, Vlatkovic R, Borcic B, Mihajic Z. Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine. Dev Biol Stand 1986; 65:95-100.
20. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, Glezen WP, Wittes J. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: A randomized controlled trial. JAMA 1999; 282:137-44.
21. Janssens HM, de Jongste JC, Fokkens WJ, Robben SG, Wouters K, Tiddens HA. The sophia anatomical infant nose-throat (saint) model: A valuable tool to study aerosol deposition in infants. J Aerosol Med 2001; 14:433-41.
22. Coates AL, Tipples G, Leung K, Gray M, Louca E. How many infective viral particles are necessary for successful mass measles immunization by aerosol? Vaccine 2006; 24:1578-85.
23. Dublecco R, Ginsberg HS. Virology. Philadelphia: Harper and Row, 1980.
24. Bennett JV, Fernandez de Castro J, Valdespino-Gomez JL, Garcia-Garcia Mde L, Islas-Romero R, Echaniz-Aviles G, Jimenez-Corona A, Sepulveda-Amor J. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: Randomized trials in Mexican schoolchildren. WHO Bulletin 2002; 80:806-12.
25. Sepulveda-Amor J, Valdespino-Gomez JL, Garcia-Garcia Mde L, Bennett J, Islas-Romero R, Echaniz-Aviles G, de Castro JF. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 2002; 20:2790-5.